JPRN-jRCT2080222940未知1 期
Phase I Study of EOS789
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 112
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 44age old（—）
- 性别
- Male
入选标准
- •Japanese or Caucasian healthy male volunteers aged 20 to 44 years
- •Body mass index (BMI) between 18.5 and 25.0 kg/m^2 for Japanese subjects and 18.5 and 30.0 kg/m^2 for Caucasian subjects at the time of screening
排除标准
- •Evidence of any cardiovascular, renal, hepatic, gastrointestinal, hematologic, immunologic, nervous, endocrine, metabolic, pulmonary disorders or history of these disorders with renal, hepatic, cardiac function disorder
研究者
相似试验
进行中（未招募）
1 期
ONO-4578-03:ONO-4578 Phase 1 StudyJPRN-jRCT2051200096Hirashima Yoshinori30
进行中（未招募）
1 期
ONO-7913-04: ONO-7913 Phase 1 StudyJPRN-jRCT2051210038Hirashima Yoshinori60
进行中（未招募）
不适用
A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to the last prior therapy for their disease. - E7389-G000-211ocally advanced or metastatic breast cancerMedDRA version: 8.1Level: PTClassification code 10055113EUCTR2005-003656-35-ATEisai Limited300
进行中（未招募）
不适用
A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to the last prior therapy for their disease. - E7389-G000-211EUCTR2005-003656-35-DEEisai Limited300
进行中（未招募）
不适用
A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to the last prior therapy for their disease. - E7389-G000-211EUCTR2005-003656-35-ESEisai Limited300